NEW DELHI : US-based biopharmaceutical major Gilead Sciences said on Wednesday it is negotiating long-term voluntary licences with several generic drugmakers in India to produce remdesivir for developing countries.
Remdesivir is an investigational antiviral drug that is being studied in multiple ongoing international clinical trials but its safety and efficacy for the treatment of COVID-19 are not yet established. "Gilead will provide appropriate technology transfers to facilitate this production," the company said in a statement. "Gilead is in discussions with some of the world's leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the